Comparison of tolerability and adverse events following treatment with two GnRH agonists in patients with advanced prostate cancer - Abstract

This multicenter, randomized, crossover, open-label study (ClinicalTrials.gov identifier: NCT01161563) assessed patients' and clinicians' perceptions of injection site tolerability and adverse events following the intramuscular injection of triptorelin pamoate or subcutaneous injection of leuprolide acetate in 107 male, patients with advanced prostate cancer.

Written by:
Shore ND¹, Sieber P², Schimke L², Perzin A³, Olsen S⁴   Are you the author?
¹Atlantic Urology Clinics, USA ²Lancaster Urology, Lancaster, PA, USA ³Delaware Valley Urology, Mt. Laurel, NJ, USA ⁴Watson Pharmaceuticals, Salt Lake City, UT, USA

Reference: Urol Nurs. 2013 Sep-Oct;33(5):236-44, 248

PubMed Abstract
PMID: 24354113

UroToday.com mCRPC Treatment Section